WO2008018133A1 - Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau - Google Patents
Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau Download PDFInfo
- Publication number
- WO2008018133A1 WO2008018133A1 PCT/JP2006/315808 JP2006315808W WO2008018133A1 WO 2008018133 A1 WO2008018133 A1 WO 2008018133A1 JP 2006315808 W JP2006315808 W JP 2006315808W WO 2008018133 A1 WO2008018133 A1 WO 2008018133A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- agent
- extract
- plant
- plant extract
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 238000009825 accumulation Methods 0.000 title claims abstract description 23
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 title abstract description 14
- 230000003020 moisturizing effect Effects 0.000 title abstract description 14
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title abstract description 3
- 239000007854 depigmenting agent Substances 0.000 title abstract 2
- 239000000284 extract Substances 0.000 claims abstract description 49
- 241000196324 Embryophyta Species 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 17
- 241000196128 Osmundaceae Species 0.000 claims abstract description 8
- 230000007935 neutral effect Effects 0.000 claims description 21
- 230000002087 whitening effect Effects 0.000 claims description 17
- 239000012190 activator Substances 0.000 claims description 11
- 239000003112 inhibitor Substances 0.000 claims description 11
- 239000004909 Moisturizer Substances 0.000 claims description 8
- 230000001333 moisturizer Effects 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 5
- 235000015277 pork Nutrition 0.000 claims 1
- 239000000419 plant extract Substances 0.000 description 54
- 210000003491 skin Anatomy 0.000 description 46
- 230000000694 effects Effects 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000002609 medium Substances 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 24
- 238000011156 evaluation Methods 0.000 description 24
- 239000000523 sample Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000000203 mixture Substances 0.000 description 21
- 235000019197 fats Nutrition 0.000 description 20
- 238000000605 extraction Methods 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 230000020411 cell activation Effects 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000008213 purified water Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 241000237502 Ostreidae Species 0.000 description 12
- 235000020636 oyster Nutrition 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- -1 ethylene, propylene, ethanol Chemical class 0.000 description 11
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 10
- 239000003205 fragrance Substances 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- 238000004945 emulsification Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000002500 effect on skin Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 241001137223 Crenichthys Species 0.000 description 6
- 241000196127 Osmunda Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000008346 aqueous phase Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000008099 melanin synthesis Effects 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 230000036548 skin texture Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940058015 1,3-butylene glycol Drugs 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- 230000002292 Radical scavenging effect Effects 0.000 description 5
- 102000042303 SPRING family Human genes 0.000 description 5
- 108091078185 SPRING family Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 235000019437 butane-1,3-diol Nutrition 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 238000010899 nucleation Methods 0.000 description 5
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001339 epidermal cell Anatomy 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 206010039897 Sedation Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 235000009697 arginine Nutrition 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000001587 sorbitan monostearate Substances 0.000 description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 description 3
- 229940035048 sorbitan monostearate Drugs 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000004200 microcrystalline wax Substances 0.000 description 2
- 235000019808 microcrystalline wax Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000219317 Amaranthaceae Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241001414720 Cicadellidae Species 0.000 description 1
- 240000001008 Dimocarpus longan Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 235000000235 Euphoria longan Nutrition 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 241000124879 Grus leucogeranus Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 240000001463 Mertensia maritima Species 0.000 description 1
- 235000011168 Mertensia maritima Nutrition 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 244000119329 Osmunda cinnamomea Species 0.000 description 1
- 235000007889 Osmunda cinnamomea Nutrition 0.000 description 1
- 241000294177 Osmunda lancea Species 0.000 description 1
- 241000676855 Osmunda x intermedia Species 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 241000294198 Plenasium banksiifolium Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000294518 Todea Species 0.000 description 1
- 235000012363 Tragopogon porrifolius Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9741—Pteridophyta [ferns]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
Definitions
- Moisturizer cell activator, whitening agent, neutral fat accumulation inhibitor, antioxidant, and topical skin preparation
- the present invention relates to a humectant, a cell activator, a whitening agent, a neutral fat accumulation inhibitor, an antioxidant, and an external preparation for skin, which comprise a naturally derived component as an active ingredient. For more information, click here
- the present invention relates to a moisturizer, a cell activator, a whitening agent, a neutral fat accumulation inhibitor, an antioxidant, and a skin external preparation containing a plant extract.
- orchidaceae plants see JP 2002-205933
- agar extract see JP 2002-193820
- peanut seed coat extract JP 2002-14575
- psyllium extract see JP 2002-145756 A
- longan seed extract see JP 2002-145732 A
- leafhopper extract see JP 2002-14573 1).
- the present invention relates to a moisturizer, cell activator, whitening agent, neutral fat accumulation inhibitor, comprising one or more plants selected from genus genus or an extract thereof as an active ingredient, Or relates to antioxidants.
- Another aspect of the present invention relates to a skin external preparation characterized by containing one or two or more kinds of plants selected from the genus genus plants or extracts thereof.
- a moisturizer, cell activator, whitening agent having an excellent effect can be obtained by using one or two or more plants selected from the genus genus plant or an extract thereof as an active ingredient.
- Agents, neutral fat accumulation inhibitors, and antioxidants can be provided.
- moisturizers When these moisturizers, cell activators, whitening agents, neutral fat accumulation inhibitors, and antioxidants are added to skin external preparations such as cosmetics and external medicines, wrinkles, tarmi, reduced skin elasticity, It is possible to provide various compositions that exhibit excellent effects in preventing and improving the appearance of various skin symptoms such as dullness.
- Osmundaceae plant is a primitive fern plant, and the genus Osm unda, Todea, and Lentonteris are known.
- Osmunda plants include: Osmunda iaponica, Osmunda reealis, Osmunda lancea, Osmunda intermedia, Osmunda cinnamomea, Omunda cinnamomea, mundo clavtoniana) and Osmunda banksiifolia are known.
- any part such as a spore body or gametophyte root, stem, trunk, leaf, or young shoot, which is not particularly limited, can be used. Use multiple parts in combination.
- any part of the spirophytes or gametophytes of the oyster family can be used.
- the whole plant, root, leaf blade, petiole, etc. of the spore body can be used. Good.
- an extract may be obtained using a plurality of parts. You can also use a mixture of two or more extracts extracted using different solvents.
- the plant may be used as it is. However, considering the extraction efficiency, it is preferable to perform the extraction after processing such as shredding, drying, and powdering.
- the extraction can be performed by immersing in an arbitrary extraction solvent for a predetermined time.
- the extraction solvent may be heated as necessary.
- extraction can be performed using a supercritical fluid or a subcritical fluid.
- the mixture may be stirred or homogenized in an extraction solvent.
- the extraction temperature is suitably about 5 ° C to the boiling point of the extraction solvent.
- Extraction solvents include water, lower alcohols such as methanol, ethanol, propanol, and isopropanol; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerine; ethyl ether, propyl ether Solvents such as ethers such as butyl acetate, butyl acetate, ethyl acetate and the like; ketones such as acetone, ethylmethyl ketone and the like can be used. These may be used alone or in combination of any two or more. Saline, phosphate buffer, phosphate buffered saline and the like may be used. In addition, one or more supercritical liquids such as water, carbon dioxide, ethylene, propylene, ethanol, methanol, ammonia, etc. A field liquid may be used.
- the extract of the oyster family plant using the above-mentioned solvent may be used as it is. It may be left as it is for a certain period of time to be aged, or the concentrated and dried product may be used again as water or a polar solvent. It can also be used by dissolving. Alternatively, it may be used after performing purification treatment such as decolorization, deodorization and desalting, and fractionation treatment by column chromatography or the like within the range not impairing these physiological functions.
- the above-mentioned extracts of the oyster family plants and their treated products and fractions can be freeze-dried after each treatment and fractionation and dissolved in a solvent at the time of use. Moreover, it can also be used by being encapsulated in vesicles such as ribosomes, microcapsules and the like.
- the genus plant or extract thereof has an excellent moisturizing action, cell activation action, whitening action, neutral fat accumulation inhibiting action, antioxidant action, moisturizing agent, cell activator, whitening agent, neutrality It can be used as a fat accumulation inhibitor and an antioxidant.
- Each of these agents is not limited at all in terms of its form and the presence or absence of other components as long as it contains a genus plant or its extract as an active ingredient.
- any form such as liquid, paste, gel, solid, powder, etc. can be selected according to its use etc., and the vehicle (excipient), solvent, Other general additives (anti-oxidation agent, colorant, dispersant, etc.) can optionally be included.
- a moisturizing agent containing a spring family plant or an extract thereof as an active ingredient provides an excellent moisturizing effect on the skin and hair, etc., and also has an excellent effect on improving rough skin, fine lines, dullness and skin symptoms. Demonstrate, improve skin texture and enhance skin transparency.
- a cell activator comprising a spring family plant or an extract thereof as an active ingredient has an excellent dermal fibroblast activation effect and an epidermal cell activation effect, and exhibits an excellent cell activation effect.
- a whitening agent comprising an Amaranthaceae plant or an extract thereof as an active ingredient has an excellent melanin production inhibitory effect and tyrosinase activity inhibitory effect, and is excellent in preventing and improving pigmentation, stains, freckles, etc. Demonstrate whitening effect.
- a neutral fat accumulation inhibitor comprising a spring plant or an extract thereof as an active ingredient has an excellent neutral fat accumulation inhibitory effect and exhibits an excellent neutral fat accumulation inhibitory effect.
- An antioxidant containing an apricot family plant or an extract thereof as an active ingredient is an excellent radical. It has an excellent anti-oxidant effect and has an erasing effect of superoxide-on and superoxide-on.
- a variety of skins such as wrinkles, tarmi, stains, dullness, dryness, fine wrinkles, etc. are obtained by blending the spring power plant or its extract into a skin external preparation such as cosmetics, topical pharmaceuticals, and quasi drugs. Prevention of symptoms ⁇
- a skin external preparation such as cosmetics, topical pharmaceuticals, and quasi drugs.
- Prevention of symptoms ⁇ An external preparation for skin that exhibits an excellent improvement effect can be obtained. Therefore, it can be preferably used as, for example, a moisturizing skin external preparation or a whitening skin external preparation.
- the amount of the spring power plant or the extract thereof in the external preparation for skin can be adjusted according to the type and purpose of the external preparation for skin, but the total amount of the external preparation for skin from the viewpoint of the effect and stability.
- 0.0001 to 10.0% by mass is more preferable, 0.001 to 5.0% by mass, still more preferably 0.01 to 5% by mass. , rather more preferably is 0.1 to 5 mass 0/0.
- the dosage form of the external preparation for skin is arbitrary, and for example, various dosage forms such as lotion, emulsion, gel, cream, ointment, powder, granule, pack, patch, patch, aerosol, etc. Can be provided.
- the topical skin preparation is usually used for pharmaceuticals, quasi-drugs, skin cosmetics, hair cosmetics and cleansing agents, etc., depending on the use and necessity.
- Optional ingredients to be formulated such as water, oily ingredients, humectants, powders, pigments, emulsifiers, solubilizers, gelling agents, cleaning agents, UV absorbers, anti-inflammatory agents, thickeners, pH adjusters, Surfactants, chelating agents, drugs (medicinal ingredients), fragrances, rosin, antibacterial and antifungal agents, antioxidants, alcohols and the like can be appropriately blended.
- other moisturizers, cell activators, whitening agents, neutral fat accumulation inhibitors, antioxidants, or combinations of plants other than the genus family or extracts thereof Is also possible.
- DMEM Dulbecco's modified Eagle medium
- the medium was replaced with 1% by mass FBS-added DMEM medium to which the sample (extract) was added so as to have each concentration shown in Table 1, and further cultured for 48 hours. After removing the supernatant, replace with medium containing 400 gZmL of 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide (MTT) and incubate for about 2 hours did. Thereafter, the formazan produced by the opening of the tetrazolium ring was extracted with 2-propanol, and the absorbance at 550 nm was measured with a microplate reader.
- MTT 3- (4,5-dimethyl-2-thiazolyl) -2,5-diphenyltetrazolium bromide
- the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
- the medium containing the sample In addition to the 1 mass 0 / oFBS ⁇ Ka ⁇ DMEM medium as a negative control, using 5 mass 0 / oFBS ⁇ Ka ⁇ DMEM medium as a positive control.
- Human epidermal non-keratinized cells were seeded in 96-well microplates at 2.0 ⁇ 10 4 cells per well.
- a seeding medium commercially available Humedia-KG2 manufactured by Kurabo Industries, Ltd. was used. After culturing for 24 hours, the medium was replaced with the test medium to which the sample was added at the concentrations shown in Table 2, and further cultured for 24 hours. Next, the medium was replaced with a medium containing 100 ⁇ gZmL of 3- (4,5 dimethyl-2 thiazolyl) 2,5 diphenyltetrazolium bromide (MTT) and cultured for 2 hours. -Extracted with propanol, and the absorbance at 550 nm was measured with a microplate reader. At the same time, the absorbance at 650 nm was measured as turbidity, and the cell activation effect was evaluated by the difference between the two measured values.
- the evaluation results show the cell activation effect in the control using the medium without sample.
- Table 2 shows the relative values when 0 is assumed.
- B16 mouse melanoma cells (B16F0 cells) were seeded at a density of 1.8 ⁇ 10 4 per dish.
- the seeding medium used was Dulbecco's modified Eagle medium (DMEM) supplemented with 5% by weight urine fetal serum (FBS). After 24 hours, the medium was replaced with a sample-added medium adjusted to each concentration shown in Table 4 using a DMEM medium supplemented with 5% by mass FBS, and further cultured for 5 days. After completion of the culture, the cells were detached with trypsin, transferred to a 1.5 mL microtube, and centrifuged to obtain a cell precipitate. The color of the obtained precipitate was visually judged based on the judgment table shown in Table 3.
- DMEM Dulbecco's modified Eagle medium
- FBS urine fetal serum
- the evaluation is based on a five-point scale.
- DMEM medium containing 5% FBS without sample added to the negative control (judgment 5) and 50 mM sodium lactate contained in the positive control (judgment 1) DMEM containing 5 mass 0 / oFBS Medium was used.
- the cells were completely lysed by exchanging with 75 L of 1% by mass Triton-X-containing phosphate buffer, and 50 / zL of the cell was used as a crude enzyme solution.
- 0.05 mass% L-dopa-containing phosphate buffer solution 50 / zL as a substrate was added and allowed to stand at 37 ° C. for 2 hours.
- Microplate reader 4 immediately after substrate addition and at the end of the reaction Absorbance at 05 nm was measured, and the amount of dopamelanin produced was determined by introducing each measured value into Equation (1).
- the amount of protein in each well was measured using BIER Protein Assay Kit manufactured by PIERCE, and the amount of dopamelanin produced per unit protein was determined.
- the measurement results are shown in Table 5 according to the inhibition rate based on the value of the control using the culture medium without sample.
- Subcutaneous fat-derived normal human preadipocytes Cryo ⁇ HPRAD SQ (Sanko Junyaku Co., Ltd.) were seeded on a 96-well microphone mouthplate so that there were 1.0 ⁇ 10 4 cells per well.
- PGM medium (10% by weight urinary fetal serum (FBS), 2 mM L Glutamine, 1 OOunits / mL Penicilline, 100 ⁇ g Z mL Streptomycine3 ⁇ 4′3 ⁇ 4) was used.
- PGM-diluted medium supplemented with the sample concentrations shown in Table 6 (10 ⁇ g / mL insulin, 1 M Dexamethasone, 200 ⁇ Indomethacin, 50 0 M Isobutyl—containing methylxanthine) to induce differentiation into adipocytes.
- the cells were cultured for 10 to 14 days until the control group matured and many lipid droplets accumulated in the cells. After the cells were collected, the cells were fixed using 10% neutral buffered formaldehyde solution. After washing with PBS, 0.5 wZv% Oil Red O solution was added and incubated at 37 ° C for 2 hours.
- the concentration of each sample was adjusted with 50% by mass ethanol to obtain a sample solution, and 100 / zL was added to a 96-well microplate so that the concentrations shown in Table 7 were obtained. Thereto, 0.2 mM of 1,1-diphenyl-2-picrylhydrazyl (DPPH) ethanol solution was added in an amount of 100 ⁇ L, mixed well, and allowed to stand at room temperature in the dark for 24 hours. Thereafter, the absorbance at 516 nm derived from the DPPH radical was measured.
- the extinction rate of DPPH radicals is defined as (A) where the absorbance of the control when the sample is added and when the force is applied is (B) and the absorbance when the sample is added is (B). Introduced into equation (2). The results are shown in Table 7.
- Windmill plant extract (Preparation method 1) 3.0 Production method: Heat-dissolve the oil phase components of (1) to (6) at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After emulsification, start cooling and add (11) and (12) in order to make uniform To mix.
- Windmill plant extract (Preparation method 3) 5.0 Production method: Dissolve (2) and (3) in (1). After dissolution, add (4) to (8) sequentially, then stir well, add (9), and mix uniformly.
- Windmill plant extract (Preparation method 1) 5.0 Production method: Heat-dissolve the oil phase components of (1) to (6) at 80 ° C. On the other hand, the aqueous phase components (7) to (10) are heated and dissolved at 80 ° C. The oil phase component is added to this while stirring and uniformly emulsified with a homogenizer. After the emulsification, add (11) and start cooling at 40 ° C (12) And mix evenly.
- Windmill plant extract (Preparation method 2) 50 Manufacturing method: Mix the aqueous phase components (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the oil phase components (7) to (14) are mixed and dissolved by heating at 75 ° C. Next, the oil phase component is added to the aqueous phase component and preliminary emulsification is performed, followed by uniform emulsification with a homomixer. Start cooling after emulsification and cover (15) at 50 ° C. Cool to 40 ° C, add (16), and mix evenly.
- Windmill plant extract (Preparation method 3) 4.0 Production method: Dissolve (1) and (2) uniformly. Add (3) and (4) to this, and mix evenly.
- Windmill plant extract (Preparation method 3) 5.0 Production method: The oil phase components (1) to (4) are heated and dissolved at 80 ° C. On the other hand, the water phase components (5) to (7) are heated and dissolved at 80 ° C, and the oil phase components are mixed and stirred uniformly. Start cooling at 40 ° C Add (8) and mix evenly.
- Windmill plant extract (Preparation method 2) 3.0 Manufacturing method: Mix the oil phase components of (1) to (4), and dissolve by heating at 75 ° C. On the other hand, the aqueous phase components (5) to (7) are mixed and dissolved by heating at 75 ° C. The pigments (8) to (10) are added to this and uniformly dispersed with a homomixer. Let The oil phase component is added to the water phase component and emulsified with a homomixer. Start cooling after emulsification, add ingredients (11) and (12) at 40 ° C and mix evenly.
- Windmill plant extract (Preparation method 1) 4.0 Production method: Mix the oil phase components (1) to (6) and dissolve at 75 ° C with heating. On the other hand, the water phase components (7) to (10) are mixed and dissolved by heating at 75 ° C. The pigments (11) to (15) are added to this and uniformly dispersed with a homomixer. To do. Add oil phase ingredients and emulsify. Cooling is started after emulsification, and components (16) and (17) are sequentially added at 40 ° C and mixed uniformly.
- Example 3 A use test using the external preparation for skin of Example 3 was carried out, and the moisturizing property of the spring plant extract was evaluated. At that time, the genus plant extract formulated in Example 1 was replaced with a 50% mass ethanol aqueous solution, and the genus plant extract formulated in Comparative Example 1 and Example 3 was replaced with a 50% mass ethanol aqueous solution. A test was conducted in the same manner as Comparative Example 2 using the sample.
- Each sample has rough skin, smooth skin, and clear skin! / A group of 20 to 50-year-old male and female panelists who have troubles. Each was used for 1 month with blinds, and changes in skin condition before and after use were observed and evaluated. As indicators of skin condition, rough skin, skin texture and skin transparency were evaluated in three stages: “Improved”, “Slightly improved” and “No change”. The rough skin and the transparency of the skin were evaluated visually, and the texture of the skin was observed using a microscope. Table 10 shows the number of panelists that obtained each evaluation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cosmetics (AREA)
Abstract
La présente invention concerne un agent hydratant, un agent d'activation cellulaire, un agent décolorant pour la peau, un agent suppresseur de l'accumulation de triglycérides, un antioxydant contenant, à titre de principe actif, une ou plusieurs plantes choisies parmi les plantes appartenant à la famille des Osmundaceae ou un extrait de celles-ci. L'invention concerne également une préparation externe pour la peau contenant une ou plusieurs plantes choisies parmi les plantes appartenant à la famille des Osmundaceae ou un extrait de celles-ci.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/315808 WO2008018133A1 (fr) | 2006-08-10 | 2006-08-10 | Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau |
JP2008528684A JPWO2008018133A1 (ja) | 2006-08-10 | 2006-08-10 | 保湿剤、細胞賦活剤、美白剤、中性脂肪蓄積抑制剤、抗酸化剤、及び皮膚外用剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2006/315808 WO2008018133A1 (fr) | 2006-08-10 | 2006-08-10 | Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008018133A1 true WO2008018133A1 (fr) | 2008-02-14 |
Family
ID=39032679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/315808 WO2008018133A1 (fr) | 2006-08-10 | 2006-08-10 | Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2008018133A1 (fr) |
WO (1) | WO2008018133A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102021124078A1 (de) | 2021-09-17 | 2023-03-23 | Timm Golüke | Kosmetikzusammensetzung zur Anwendung auf der Haut |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03218466A (ja) * | 1989-02-06 | 1991-09-26 | Chiba Seifun Kk | リムラステスト陽性植物糖脂質、それらを含む免疫機能活性化剤、動物用免疫機能活性化剤、免疫機能検査薬、動物用免疫機能検査薬、医薬部外品、化粧品、食品、機能性食品、飲料、飼料 |
JPH0449244A (ja) * | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | 抗糖尿病剤、動物用抗糖尿病剤 |
JPH06340532A (ja) * | 1993-06-01 | 1994-12-13 | Nippon Beet Sugar Mfg Co Ltd | 血中脂質の上昇抑制又は低減剤 |
US20040126344A1 (en) * | 2002-12-26 | 2004-07-01 | Avon Products, Inc. | Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation |
JP2006508171A (ja) * | 2002-12-26 | 2006-03-09 | エイボン プロダクツ インコーポレーテッド | 天然成分を含有する局所用組成物及び使用方法 |
JP2006514997A (ja) * | 2003-05-12 | 2006-05-18 | エイボン プロダクツ インコーポレーテッド | 皮膚の審美的外観を改善する化粧品組成物及びそれを使用する方法 |
-
2006
- 2006-08-10 WO PCT/JP2006/315808 patent/WO2008018133A1/fr active Application Filing
- 2006-08-10 JP JP2008528684A patent/JPWO2008018133A1/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03218466A (ja) * | 1989-02-06 | 1991-09-26 | Chiba Seifun Kk | リムラステスト陽性植物糖脂質、それらを含む免疫機能活性化剤、動物用免疫機能活性化剤、免疫機能検査薬、動物用免疫機能検査薬、医薬部外品、化粧品、食品、機能性食品、飲料、飼料 |
JPH0449244A (ja) * | 1990-06-15 | 1992-02-18 | Chiba Seifun Kk | 抗糖尿病剤、動物用抗糖尿病剤 |
JPH06340532A (ja) * | 1993-06-01 | 1994-12-13 | Nippon Beet Sugar Mfg Co Ltd | 血中脂質の上昇抑制又は低減剤 |
US20040126344A1 (en) * | 2002-12-26 | 2004-07-01 | Avon Products, Inc. | Compositions having glycolipid to lighten skin and alter post-inflammatory hyperpigmentation |
JP2006508171A (ja) * | 2002-12-26 | 2006-03-09 | エイボン プロダクツ インコーポレーテッド | 天然成分を含有する局所用組成物及び使用方法 |
JP2006514997A (ja) * | 2003-05-12 | 2006-05-18 | エイボン プロダクツ インコーポレーテッド | 皮膚の審美的外観を改善する化粧品組成物及びそれを使用する方法 |
Non-Patent Citations (1)
Title |
---|
HAYASHI M. ET AL.: "Noto no Sansai o Katsuyo shita Tokusanhin Kaihatsu II Sansai no Kinosei no Kensaku (Studies on the development of the principal products maked from edible wild plants cultivated in the northern area of Ishikawa prefecture)", BULLETIN OF THE ISHIKAWA AGRICULTURE RESEARCH CENTER, no. 24, 2002, pages 61 - 64, XP003021027 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102021124078A1 (de) | 2021-09-17 | 2023-03-23 | Timm Golüke | Kosmetikzusammensetzung zur Anwendung auf der Haut |
WO2023041411A1 (fr) * | 2021-09-17 | 2023-03-23 | Golueke Timm | Composition cosmétique destinée à être utilisée sur la peau |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008018133A1 (ja) | 2009-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5557414B2 (ja) | 保湿剤、細胞賦活剤、及び美白剤 | |
JP2008063266A (ja) | 抗老化剤、美白剤、抗酸化剤、および抗炎症剤 | |
JP2010070501A (ja) | 保湿剤、抗老化剤、抗酸化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、皮膚外用剤、経口用剤 | |
JP5117092B2 (ja) | 保湿剤、抗老化剤、美白剤、抗酸化剤、痩身剤、トリートメント剤、アルギナーゼ活性促進剤及び皮膚外用剤 | |
JP5014343B2 (ja) | ネマガリダケ含有組成物、保湿剤、細胞賦活剤、美白剤及び抗酸化剤 | |
JP5312731B2 (ja) | 皮膚外用剤 | |
JP4689215B2 (ja) | 保湿剤、細胞賦活剤、美白剤、及びコラゲナーゼ阻害剤 | |
JP2007277100A (ja) | 保湿剤、細胞賦活剤、真皮線維芽細胞賦活剤、表皮細胞賦活剤、コラーゲン産生促進剤、抗酸化剤、抗老化剤、美白剤、メラニン産生抑制剤 | |
JP5247548B2 (ja) | 保湿剤、抗老化剤、中性脂肪蓄積抑制剤、美白剤、抗炎症剤、皮膚外用剤、経口用剤 | |
JP5465037B2 (ja) | 抗老化剤、抗酸化剤、美白剤、免疫賦活剤、皮膚外用剤および機能性経口組成物 | |
WO2008018133A1 (fr) | Agent hydratant, agent d'activation cellulaire, agent décolorant pour la peau, agent suppresseur de l'accumulation de triglycérides, antioxydant et préparation externe pour la peau | |
JP5025201B2 (ja) | 保湿剤、抗老化剤、美白剤、抗炎症剤、及び抗酸化剤 | |
JP4748962B2 (ja) | 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤 | |
JP4970442B2 (ja) | 美白剤 | |
JP4050727B2 (ja) | 保湿剤、細胞賦活剤、美白剤、抗酸化剤、及び皮膚外用剤 | |
JP5388555B2 (ja) | 保湿剤、抗老化剤、抗酸化剤、痩身剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、機能性経口組成物 | |
JP4931452B2 (ja) | 保湿剤、細胞賦活剤、美白剤、及び抗酸化剤 | |
JP4994684B2 (ja) | 保湿剤、細胞賦活剤、及び抗酸化剤 | |
JP2008231016A (ja) | 皮膚外用剤、保湿剤、抗老化剤、抗酸化剤、抗炎症剤、美白剤、及び痩身剤 | |
JP4291647B2 (ja) | 細胞賦活剤、美白剤、コラーゲン産生促進剤、抗酸化剤、及び皮膚外用剤 | |
JP5313003B2 (ja) | 保湿剤 | |
JP5265489B2 (ja) | 保湿剤、抗老化剤、抗酸化剤、美白剤、抗炎症剤、免疫賦活剤、皮膚外用剤、経口用剤 | |
JP4869638B2 (ja) | 細胞賦活剤、美白剤、抗酸化剤、アミラーゼ阻害剤、及び保湿剤 | |
JP5009544B2 (ja) | 保湿剤、細胞賦活剤、抗酸化剤、及びコラゲナーゼ阻害剤 | |
JP5013726B2 (ja) | 保湿剤、細胞賦活剤、抗酸化剤、及びコラゲナーゼ阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 06782612 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008528684 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06782612 Country of ref document: EP Kind code of ref document: A1 |